Targeting the key autophagy protease ATG4B in BCR-ABL+ human leukemia

靶向 BCR-ABL 人类白血病中的关键自噬蛋白酶 ATG4B

• 批准号: 386605
• 负责人: Shen Yueyang
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-12-01 至 2018-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=386605&lang=en
• 关键词: Atg4b; Atg4b Inhibitors; Autophagy; Bcr-Abl; Caloric Restriction; Chronic Myeloid Leukemia; Drug Resistance; Leukemic Stem Cell; Tyrosine Kinase Inhibitors; Xeno-Transplant Mouse Model

Blood cancer (leukemia) is common, with ~55,000 cases expected in the United States and Canada in 2017.According toNational Cancer Institute (US),the 5-year survival rate for leukemia is 56%. Durg resistance and relapse pose significant challenges. Life-l

血癌（白血病）很常见，预计2017年在美国和加拿大约有55,000例。根据美国国家癌症研究所的数据，白血病的5年生存率为56%。耐药性和复发构成了重大挑战。Life-l